Hong J H, Tsai C S, Wang C C, Lai C H, Chen W C, Lee S P, Chang T C, Tseng C J
Department of Radiation Oncology, Chang Gung Memorial Hospital, Taipei, Taiwan, R.O.C.
Chang Gung Med J. 2000 Jul;23(7):396-404.
Adenocarcinomas/adenosquamous carcinomas (AC/ASC) are relatively uncommon histological subtypes in cervical cancer. In this study, we retrospectively compared the clinical behaviors and responses to radiation of squamous cell carcinomas (SCC) and AC/ASC in patients with stage I-IVA cervical cancer primarily treated by radiotherapy (RT).
Nine hundred twenty-eight patients with cervical cancer primarily treated with RT were included in this study. Ninety-four percent of the patients had SCC and 6% had AC/ASC. The association of histological subtype to various clinical parameters was assessed. Tumor response and failure patterns were analyzed, and the prognostic significance of histological subtype and other clinical parameters were evaluated by univariate and multivariate analyses.
(1) Patients with AC/ASC had a significantly higher percentage of bulky I-IIA disease, a younger age (< 45 years), and an elevated carcinoembryonic antigen (CEA) level, but a lower percentage of elevated squamous cell carcinoma antigen (SCC-Ag) level, than patients with SCC. Hemoglobin (Hb) levels and lymph node status were not significantly different between SCC and AC/ASC patients. (2) A higher percentage of AS/ASC patients had residual induration 2 to 3 months after RT than those with SCC (40% vs. 21.6%, p = 0.008). Higher local failure rates were found for AC/ASC patients compared to SCC patients (38% vs. 15%, p = 0.001). (3) The 5-year disease-specific survival rate was 66% and 50% for SCC and AC/ASC patients, respectively (p = 0.016). Advanced stages, Hb levels lower than 10 g/dl, positive lymph nodes, AC/ASC histological subtype, and SCC-Ag levels higher than 10 ng/ml were independent prognostic factors for worse survival for all patients. For patients with AC/ASC in particular, only stage and positive lymph nodes were significant prognostic factors.
Cervical cancer patients with AC/ASC are relatively younger and have a higher incidence of elevated CEA and a lower incidence of elevated SCC-Ag levels than those with SCC. For AC/ASC patients, the tumor responses to RT were relatively slow and poor. This group of patients had a worse survival rate than patients with SCC, mainly because of the higher incidence of uncontrolled local disease for AC/ASC patients.
腺癌/腺鳞癌(AC/ASC)是宫颈癌中相对少见的组织学亚型。在本研究中,我们回顾性比较了主要接受放疗(RT)的Ⅰ - ⅣA期宫颈癌患者中鳞状细胞癌(SCC)和AC/ASC的临床行为及对放疗的反应。
本研究纳入了928例主要接受RT治疗的宫颈癌患者。94%的患者为SCC,6%为AC/ASC。评估了组织学亚型与各种临床参数的相关性。分析了肿瘤反应和失败模式,并通过单因素和多因素分析评估了组织学亚型及其他临床参数的预后意义。
(1)与SCC患者相比,AC/ASC患者中体积较大的Ⅰ - ⅡA期疾病比例显著更高,年龄更小(<45岁),癌胚抗原(CEA)水平升高,但鳞状细胞癌抗原(SCC-Ag)水平升高的比例更低。SCC和AC/ASC患者之间的血红蛋白(Hb)水平和淋巴结状态无显著差异。(2)放疗后2至3个月,AC/ASC患者残留硬结的比例高于SCC患者(40%对21.6%,p = 0.008)。与SCC患者相比,AC/ASC患者的局部失败率更高(38%对15%,p = 0.001)。(3)SCC和AC/ASC患者的5年疾病特异性生存率分别为66%和50%(p = 0.016)。晚期、Hb水平低于10 g/dl、淋巴结阳性、AC/ASC组织学亚型以及SCC-Ag水平高于10 ng/ml是所有患者生存较差的独立预后因素。对于AC/ASC患者而言,只有分期和淋巴结阳性是显著的预后因素。
与SCC患者相比,AC/ASC宫颈癌患者相对更年轻,CEA水平升高的发生率更高,SCC-Ag水平升高的发生率更低。对于AC/ASC患者,放疗后的肿瘤反应相对较慢且较差。该组患者的生存率低于SCC患者,主要原因是AC/ASC患者局部疾病控制不佳的发生率更高。